(Circulation. 1998;98:2415-2421.)
© 1998 American Heart Association, Inc.
Clinical Investigation and Reports |
Percutaneous Transluminal Septal Myocardial Ablation in Hypertrophic Obstructive Cardiomyopathy
Results With Respect to Intraprocedural Myocardial Contrast Echocardiography
From the Department of Cardiology, Heart Center NRW, Ruhr-University of Bochum, Bad Oeynhausen, Germany.
Correspondence to PD Dr Hubert Seggewiss, Department of Cardiology, Heart and Diabetes Center NRW, Ruhr-University of Bochum, Georgstr 11, D-32545 Bad Oeynhausen, FRG. E-mail seggewiss.hubert{at}t-online.de
Background—Percutaneous transluminal septal myocardial ablation (PTSMA) has been introduced as an alternative procedure for reducing the left ventricular outflow tract gradient (LVOTG) in hypertrophic obstructive cardiomyopathy. We report on the acute and mid-term results in 91 symptomatic patients with respect to intraprocedural myocardial contrast echocardiography (MCE).
Methods and Results—PTSMA was intended for 46 women and 45 men (54.1±15.5 years). In 2 patients, the intervention could not be completed. In the first 30 patients the target vessel was determined by probatory balloon occlusion alone and in the remainder by additional intraprocedural MCE. Resting LVOTG was reduced from 73.8±35.4 to 16.6±18.1 and nostextrasystolic LVOTG from 149.3±42.5 to 61.9±43.0 mm Hg (P<0.0001 each). In 10 (11%) patients, permanent DDD pacemaker implantation was necessary. Two (2%) patients died, 1 from ventricular fibrillation associated with treatment for chronic obstructive pulmonary disease after 9 days and 1 from fulminant pulmonary embolism after 2 days. After 3 months, mean New York Heart Association class was reduced from 2.8±0.6 to 1.1±1.0 (P<0.0001). The LVOTG remained reduced to 14.6±25.5 mm Hg at rest and 49.1±48.7 mm Hg (P<0.0001 each). Four patients underwent successful repeat PTSMA. Determination of the target vessel by MCE was associated with a higher rate of acute (92% vs 70%; P<0.01) and mid-term (94% vs 64%; P<0.01) success.
Conclusions—PTSMA is a promising nonsurgical technique for reduction of symptoms and LVOTG in hypertrophic obstructive cardiomyopathy. MCE has been shown to be a useful addition to probatory balloon occlusion for target vessel selection. Prospective, long-term observations of larger populations and a comparison with the established forms of therapy are necessary to determine the definitive significance of PTSMA.
Key Words: hypertrophy • cardiomyopathy • ablation • contrast media • echocardiography
This article has been cited by other articles:
 |
|
 |
|
  J. Wang, J. M. Buergler, K. Veerasamy, Y. P. Ashton, and S. F. Nagueh Delayed untwisting: the mechanistic link between dynamic obstruction and exercise tolerance in patients with hypertrophic obstructive cardiomyopathy. J. Am. Coll. Cardiol., September 29, 2009; 54(14): 1326 - 1334. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G S Soor, A Luk, E Ahn, J R Abraham, A Woo, A Ralph-Edwards, and J Butany Hypertrophic cardiomyopathy: current understanding and treatment objectives J. Clin. Pathol., March 1, 2009; 62(3): 226 - 235. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S R Ommen, P M Shah, and A J Tajik Left ventricular outflow tract obstruction in hypertrophic cardiomyopathy: past, present and future Heart, October 1, 2008; 94(10): 1276 - 1281. [Full Text] [PDF]
|
|
|
|
 |
|
 T. Butz, H.K. Schmidt, D. Fassbender, H. Esdorn, M. Wiemer, D. Horstkotte, and L. Faber Echo-guided percutaneous coil embolization of a symptomatic massive metastasis of a renal cell carcinoma in the right ventricular outflow tract Eur J Echocardiogr, September 1, 2008; 9(5): 725 - 727. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Butz, D. Horstkotte, C. Langer, H. Esdorn, G. Kleikamp, R. Korfer, and L. Faber Significant obstruction of the right and left ventricular outflow tract in a patient with biventricular hypertrophic cardiomyopathy Eur J Echocardiogr, March 1, 2008; 9(2): 344 - 345. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. A. Fifer and G. J. Vlahakes Management of Symptoms in Hypertrophic Cardiomyopathy Circulation, January 22, 2008; 117(3): 429 - 439. [Full Text] [PDF]
|
|
|
|
 |
|
 W. J. Stewart Imaging the future of transcatheter aortic valve replacement. J. Am. Coll. Cardiol. Img., January 1, 2008; 1(1): 25 - 28. [Full Text] [PDF]
|
|
|
|
 |
|
 M. W. Hansen and N. Merchant MRI of Hypertrophic Cardiomyopathy: Part 2, Differential Diagnosis, Risk Stratification, and Posttreatment MRI Appearances Am. J. Roentgenol., December 1, 2007; 189(6): 1344 - 1352. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. A. Fifer Most Fully Informed Patients Choose Septal Ablation Over Septal Myectomy Circulation, July 10, 2007; 116(2): 207 - 216. [Full Text] [PDF]
|
|
|
|
 |
|
 D. M. Yoerger, C. A. Best, B. M. McQuillan, G. E. Supple, J. L. Guererro, J. E. Cluette-Brown, A. Hasaba, M. H. Picard, J. R. Stone, and M. Laposata Rapid Fatty Acid Ethyl Ester Synthesis by Porcine Myocardium Upon Ethanol Infusion into the Left Anterior Descending Coronary Artery Am. J. Pathol., May 1, 2006; 168(5): 1435 - 1442. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. H. Yacoub Surgical Versus Alcohol Septal Ablation for Hypertrophic Obstructive Cardiomyopathy: The Pendulum Swings Circulation, July 26, 2005; 112(4): 450 - 452. [Full Text] [PDF]
|
|
|
|
|
|
R. Roberts and U. Sigwart Current Concepts of the Pathogenesis and Treatment of Hypertrophic Cardiomyopathy Circulation, July 12, 2005; 112(2): 293 - 296. [Full Text] [PDF]
|
|
|
|
|
|
W. G. van Dockum, A. M. Beek, F. J. ten Cate, J. M. ten Berg, O. Bondarenko, M. J.W. Gotte, J. W.R. Twisk, M. B.M. Hofman, C. A. Visser, and A. C. van Rossum Early Onset and Progression of Left Ventricular Remodeling After Alcohol Septal Ablation in Hypertrophic Obstructive Cardiomyopathy Circulation, May 17, 2005; 111(19): 2503 - 2508. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Hering, D. Welge, D. Fassbender, D. Horstkotte, and L. Faber Quantitative analysis of intraprocedural myocardial contrast echocardiography during percutaneous septal ablation for hypertrophic obstructive cardiomyopathy Eur J Echocardiogr, December 1, 2004; 5(6): 443 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Faber, H. Seggewiss, D. Welge, D. Fassbender, H. K. Schmidt, U. Gleichmann, and D. Horstkotte Echo-guided percutaneous septal ablation for symptomatic hypertrophic obstructive cardiomyopathy: 7 years of experience Eur J Echocardiogr, October 1, 2004; 5(5): 347 - 355. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. O. Cheng, C. D. Kimmelstiel, and B. J. Maron In Percutaneous Transluminal Septal Myocardial Ablation for Hypertrophic Obstructive Cardiomyopathy, It Is Not the Speed of Intracoronary Alcohol Injection But the Amount of Alcohol Injected That Determines the Resultant Infarct Size * Response Circulation, July 20, 2004; 110(3): e23 - e23. [Full Text] [PDF]
|
|
|
|
|
|
F H Gietzen, C J Leuner, L Obergassel, C Strunk-Mueller, and H Kuhn Transcoronary ablation of septal hypertrophy for hypertrophic obstructive cardiomyopathy: feasibility, clinical benefit, and short term results in elderly patients Heart, June 1, 2004; 90(6): 638 - 644. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, F. J. Ten Cate, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines J. Am. Coll. Cardiol., November 5, 2003; 42(9): 1687 - 1713. [Full Text] [PDF]
|
|
|
|
 |
|
 Writing Committee Members, B. J. Maron, W. J. McKenna, G. K. Danielson, L. J. Kappenberger, H. J. Kuhn, C. E. Seidman, P. M. Shah, W. H. Spencer III, P. Spirito, et al. American College of Cardiology/European Society of Cardiology Clinical Expert Consensus Document on Hypertrophic Cardiomyopathy: A report of the American College of Cardiology Foundation Task Force on Clinical Expert Consensus Documents and the European Society of Cardiology Committee for Practice Guidelines Eur. Heart J., November 1, 2003; 24(21): 1965 - 1991. [Full Text] [PDF]
|
|
|
|
 |
|
 S. Steinbis Hypertrophic Obstructive Cardiomyopathy and Septal Ablation Crit. Care Nurse, June 1, 2003; 23(3): 47 - 50. [Full Text] [PDF]
|
|
|
|
 |
|
 W. Shamim, M. Yousufuddin, D. Wang, M. Henein, H. Seggewiss, M. Flather, A. J.S. Coats, and U. Sigwart Nonsurgical Reduction of the Interventricular Septum in Patients with Hypertrophic Cardiomyopathy N. Engl. J. Med., October 24, 2002; 347(17): 1326 - 1333. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T.-H. Park, N. M. Lakkis, K. J. Middleton, J. Franklin, W. A. Zoghbi, M. A. Quinones, W. H. Spencer III, and S. F. Nagueh Acute Effect of Nonsurgical Septal Reduction Therapy on Regional Left Ventricular Asynchrony in Patients With Hypertrophic Obstructive Cardiomyopathy Circulation, July 23, 2002; 106(4): 412 - 415. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
F. H. Gietzen, C. J. Leuner, L. Obergassel, C. Strunk-Mueller, and H. Kuhn Role of Transcoronary Ablation of Septal Hypertrophy in Patients With Hypertrophic Cardiomyopathy, New York Heart Association Functional Class III or IV, and Outflow Obstruction Only Under Provocable Conditions Circulation, July 23, 2002; 106(4): 454 - 459. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. X. Qin, T. Shiota, H. M. Lever, D. N. Rubin, F. Bauer, Y. J. Kim, M. Sitges, N. L. Greenberg, J. K. Drinko, M. Martin, et al. Impact of left ventricular outflow tract area on systolic outflow velocity in hypertrophic cardiomyopathy: A real-time three-dimensional echocardiographic study J. Am. Coll. Cardiol., January 16, 2002; 39(2): 308 - 314. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Xin, T. Shiota, H. M. Lever, S. R. Kapadia, M. Sitges, D. N. Rubin, F. Bauer, N. L. Greenberg, D. A. Agler, J. K. Drinko, et al. Outcome of patients with hypertrophic obstructive cardiomyopathy after percutaneous transluminal septal myocardial ablation and septal myectomy surgery J. Am. Coll. Cardiol., December 1, 2001; 38(7): 1994 - 2000. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. D. Wigle, L. Schwartz, A. Woo, and H. Rakowski To ablate or operate? that is the question! J. Am. Coll. Cardiol., November 15, 2001; 38(6): 1707 - 1710. [Full Text] [PDF]
|
|
|
|
|
|
R. Roberts and U. Sigwart New Concepts in Hypertrophic Cardiomyopathies, Part II Circulation, October 30, 2001; 104(18): 2249 - 2252. [Full Text] [PDF]
|
|
|
|
 |
|
 U. Sigwart Non-surgical myocardial reduction for patients with hypertrophic obstructive cardiomyopathy Eur. Heart J. Suppl., October 1, 2001; 3(suppl_L): L38 - L42. [Abstract] [PDF]
|
|
|
|
|
|
P. Boekstegers, P. Steinbigler, A. Molnar, M. Schwaiblmair, A. Becker, A. Knez, R. Haberl, and G. Steinbeck Pressure-guided nonsurgical myocardial reduction induced by small septal infarctions in hypertrophic obstructive cardiomyopathy J. Am. Coll. Cardiol., September 1, 2001; 38(3): 846 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Seggewiss Percutaneous transluminal septal myocardial ablation: A new treatment for hypertrophic obstructive cardiomyopathy Eur. Heart J., May 1, 2000; 21(9): 704 - 707. [PDF]
|
|
|
|
|
|
L. Faber Acute and long-term results after TASH Eur. Heart J., April 1, 2000; 21(7): 590 - 591. [PDF]
|
|
|
|
|
|
F.H. Gietzen, CH.J. Leuner, J. Hegselmann, C. Strunk-Mueller, and H. Khun A reply Eur. Heart J., April 1, 2000; 21(7): 591 - 593. [PDF]
|
|
|
|
|
|
C. J KNIGHT Five years of percutaneous transluminal septal myocardial ablation Heart, March 1, 2000; 83(3): 255 - 256. [Full Text]
|
|
|
|
|
|
L Faber, A Meissner, P Ziemssen, and H Seggewiss Percutaneous transluminal septal myocardial ablation for hypertrophic obstructive cardiomyopathy: long term follow up of the first series of 25 patients Heart, March 1, 2000; 83(3): 326 - 331. [Abstract] [Full Text]
|
|
|
|
|
|
H. Kuhn, F.H. Gietzen, M. Schafers, M. Freick, B. Gockel, C. Strunk-Muller, E. Jachmann, and O. Schober Changes in the left ventricular outflow tract after transcoronary ablation of septal hypertrophy (TASH) for hypertrophic obstructive cardiomyopathy as assessed by transoesophageal echocardiography and by measuring myocardial glucose utilization and perfusion Eur. Heart J., December 2, 1999; 20(24): 1808 - 1817. [Abstract] [PDF]
|
|